Keywords: Vivus, Qnexa, USA, FDA, Briefing document, Obesity

Vivus submits briefing document to US FDA on obesity drug candidate Qnexa

Article | 15 December 2010

Print This

California, USA-based Vivus (Nasdaq: VVUS), as part of its continuing effort to secure regulatory approval for its obesity drug candidate ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in